Gemcitabine and carboplatin treatment in advanced NSCLC: a retrospective evaluation including elderly patients

Roberto Murialdo¹, Davide Boy¹, Francesca Bertolotti², Maria Cristina Martini², Gisella Pastorino², Giorgio Sogno², Matteo Vallauri², Lorenza Moraglio², Lucia Tixi¹, Isabella Angelini¹, Vittoria Saccà¹, Alberto Ballestro¹, and Fulvio Brema²

¹Department of Internal Medicine, “S. Martino” Hospital, Genoa; ²Department of Oncology, “S. Paolo” Hospital, Savona, Italy

ABSTRACT

Background. Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer.

Methods. Eighty-three patients with stage III-IV non-small cell lung cancer received 3 to 4 cycles of carboplatin AUC 5 on day 2 and gemcitabine 1250 mg/m² on days 1 and 8 every 21 days.

Results. The overall response rate was 43.4%. Results obtained from elderly and non-elderly groups were compared using the logrank method. Median overall survival and progression-free survival were 11 and 7 months, respectively (12 and 7 months, non-elderly group; 6.5 and 5 months, elderly group, P = 0.28 and 0.25 respectively). Grade 3-4 toxicity included neutropenia, thrombocytopenia, anemia, nausea/vomiting, and diarrhea. Incidences of grade 3-4 toxicity were similar for elderly and non-elderly patients.

Conclusions. Data confirm that carboplatin-gemcitabine is an active and well-tolerated regimen in advanced non-small cell lung cancer and could be investigated in elderly patients.

Key words: carboplatin, chemotherapy, elderly, gemcitabine, non-small-cell lung cancer.

Acknowledgments: The paper was written without involvement of Eli Lilly. No grants were paid to the authors for participation in the study.

Correspondence to: Dr. Roberto Murialdo, Department of Internal Medicine, “S. Martino” Hospital, Viale Benedetto XV 6, 16132 Genoa, Italy. Tel +39-349-3769619; fax +39-010-3537855; e-mail rozzis752000@yahoo.it

Received March 10, 2008; accepted October 2, 2008.